Dalfampridine Tablet, Film Coated, Extended Release
Product Images NDC 51407-876

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Dalfampridine (NDC 51407-876). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-876-60ol (Dalfampridine 10 mg)

This text describes a medication called Dalfampridine in the form of extended-release tablets with a dosage of 10 mg. It provides instructions that the tablets should be taken whole and not divided, crushed, chewed, or dissolved. Pharmacists are directed to dispense the Medication Guide to each patient. It also includes storage instructions to keep the medication away from children and store it at a temperature between 15°C - 30°C (59°F - 86°F). The document mentions a website for printing the Medication Guide and includes details about the tablet quantity and the revision date.*

FDA Label Image

Dalfampridine-equa (Dalfampridine Equa)

This text provides formulas to calculate creatinine clearance (CrCl) using age, weight, and serum creatinine levels. The first formula involves subtracting the age from 140 and then multiplying it by the weight in kilograms. The second formula involves multiplying the serum creatinine level in milligrams per deciliter by 72.*

FDA Label Image

Dalfampridine-fig1 (Dalfampridine Fig1)

This data seems to present a comparison between placebo and Dalfampridine Extended-release Tablets (10 mg b..d) in terms of the percentage increase in walking speed from baseline in patients. The percentage increase in walking speed ranges from 20% to 260%. The study included a placebo group (N=72) and a group taking Dalfampridine Extended-release Tablets (N=224).*

FDA Label Image

Dalfampridine-fig2 (Dalfampridine Fig2)

This text provides data on the percentage of patients in a study along with the placebo group and the group receiving Datfampridine Extended-release Tablets. It also includes the average percent increase in walking speed from the baseline. The study has N=118 for the placebo group and N=119 for the group receiving Datfampridine Extended-release Tablets 10 mg bi.d.*

FDA Label Image

Dalfampridine-struc (Dalfampridine Struc)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.